ClinicalTrials.gg
CompletedNCT05306275Updated Oct 6, 2022

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

A Phase 1 interventional study of CSL312 in Healthy Participants, sponsored by CSL Behring. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-06.

Sponsored by CSL Behring (part of CSL Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open-label, parallel-group, phase 1, single center study to assess the relative bioavailability of CSL312 administered subcutaneously via a prefilled syringe assembled to an autoinjector compared to a prefilled syringe assembled to a needle safety device in healthy, adult subjects.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Male or female 18 to 55 years of age
  • Body weight in the range of ≥ 50 kg and ≤ 100 kg, with a (BMI) of ≥ 18 kg/m2 and ≤ 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Received any live viral or bacterial vaccinations within 8 weeks of Screening or is expected to receive any live virus or bacterial vaccinations during the study or up to 4 months after last administration of the product.
  • Evidence of current active infection, including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
  • Blood pressure or pulse rate measurements outside the normal range for the subject's age
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    CSL312 AI Abdomen

    CSL312 administered subcutaneously (SC) in the abdomen via a prefilled syringe assembled to an autoinjector (AI)

    Drug: CSL312

  • Experimental
    CSL312 AI Thigh

    CSL312 administered SC in the thigh via a prefilled syringe assembled to an AI

    Drug: CSL312

  • Experimental
    CSL312 AI Arm

    CSL312 administered SC in the upper arm via a prefilled syringe assembled to an AI

    Drug: CSL312

  • Experimental
    CSL312 NSD Abdomen

    CSL312 administered SC in the abdomen via a prefilled syringe assembled to a needle safety device (NSD)

    Drug: CSL312

  • Experimental
    CSL312 NSD Thigh

    CSL312 administered SC in the thigh via a prefilled syringe assembled to a NSD

    Drug: CSL312

  • Experimental
    CSL312 NSD Arm

    CSL312 administered SC in the upper arm via a prefilled syringe assembled to a NSD

    Drug: CSL312

Interventions

  • DrugCSL312

    Factor XIIa antagonist monoclonal antibody for subcutaneous use

    Also known as: Gardacimab

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of CSL312

    Time frame: Up to 85 days post-dose

  2. Area under the concentration-time curve (AUC) from time 0 extrapolated to infinite time (AUC0-inf) of CSL312

    Time frame: Up to 85 days post-dose

Secondary outcomes

  1. Number and percentage of subjects experiencing adverse events (AEs)

    Time frame: Up to 85 days post-dose

  2. Number and percentage of subjects experiencing serious adverse events (SAEs)

    Time frame: Up to 85 days post-dose

  3. Number and percentage of subjects experiencing adverse events of special interest (AESIs)

    Time frame: Up to 85 days post-dose

  4. Number and percentage of subjects developing Anti-CSL312 antibodies

    Time frame: Up to 85 days post-dose

  5. Number and percentage of subjects with clinically significant laboratory abnormalities that are reported as AEs

    Time frame: Up to 85 days post-dose

  6. Number and percentage of subjects with injection site reactions by severity

    Time frame: Up to 48 hours post-injection

  7. Time to maximum plasma concentration (Tmax) of CSL312

    Time frame: Up to 85 days post-dose

  8. AUC from time 0 to the last measurable concentration (AUC0-last) of CSL312

    Time frame: Up to 85 days post-dose

  9. Half-life (t1/2) of CSL312

    Time frame: Up to 85 days post-dose

  10. Apparent clearance (CL/F) of CSL312

    Time frame: Up to 85 days post-dose

  11. Apparent volume of distribution (Vz/F) of CSL312

    Time frame: Up to 85 days post-dose

07

Study locations

1 site
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Sep 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Apr 1, 2022
StartActual
Apr 4, 2022
Primary completionActual
Sep 27, 2022
CompletionActual
Sep 27, 2022
Last update
Oct 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05306275
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Apr 1, 2022
Start date
Apr 4, 2022
Primary completion
Sep 27, 2022
Completion
Sep 27, 2022
Last update
Oct 6, 2022

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garadacimab

Start the discussion